Yes, that's the sentence in the latest 10-Q that followed the one that I quoted:
"Presently, the Company does not have sufficient financial resources to advance our drug candidates meaningfully or at all. Contingent upon sufficient funding, we anticipate that our efforts would primarily focus on advancement of our drug candidate Brilacidin for decreasing the incidence of severe oral mucositis as a complication of chemoradiation in Oral Mucositis."
It's like saying "We don't have enough money to move B-OM forward but if we did that's what we'd do".
In light of the Company's current cash position and its newfound need to pay old rent AND interest your sentence is akin to spitting into the wind.
News 
Market Data 
Discover 
AI
